{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:29Z","timestamp":1792979909817,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41591-024-03357-0","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:04:00Z","timestamp":1735880640000},"page":"427-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir"],"prefix":"10.1038","volume":"31","author":[{"given":"M. Ali","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-202X","authenticated-orcid":false,"given":"Jana","family":"Blazkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lela","family":"Kardava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse S.","family":"Justement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maegan R.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniqa","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6380","authenticated-orcid":false,"given":"Brooke D.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline B.","family":"Sewack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisa M.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gittens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Raymond E.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-3725","authenticated-orcid":false,"given":"Aaron S.","family":"Devanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Mangusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-4675","authenticated-orcid":false,"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-1395","authenticated-orcid":false,"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Sneller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice K.","family":"Pau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8157-1037","authenticated-orcid":false,"given":"Zabrina L.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-6911","authenticated-orcid":false,"given":"Susan","family":"Moir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-7340","authenticated-orcid":false,"given":"Tae-Wook","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"3357_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1916753","volume":"383","author":"AS Fauci","year":"2020","unstructured":"Fauci, A. S. & Lane, H. C. Four decades of HIV\/AIDS\u2014much accomplished, much to do. N. Engl. J. Med. 383, 1\u20134 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.3152","volume":"16","author":"TW Chun","year":"2015","unstructured":"Chun, T. W., Moir, S. & Fauci, A. S. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat. Immunol. 16, 584\u2013589 (2015).","journal-title":"Nat. Immunol."},{"key":"3357_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","volume":"21","author":"RJ Landovitz","year":"2023","unstructured":"Landovitz, R. J., Scott, H. & Deeks, S. G. Prevention, treatment and cure of HIV infection. Nat. Rev. Microbiol. 21, 657\u2013670 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"3357_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.7326\/M17-2242","volume":"169","author":"RM Nance","year":"2018","unstructured":"Nance, R. M. et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann. Intern. Med. 169, 376\u2013384 (2018).","journal-title":"Ann. Intern. Med."},{"key":"3357_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/QAD.0000000000003798","volume":"38","author":"A Mocroft","year":"2024","unstructured":"Mocroft, A. et al. Heavy antiretroviral exposure and exhausted\/limited antiretroviral options: predictors and clinical outcomes. AIDS 38, 497\u2013508 (2024).","journal-title":"AIDS"},{"key":"3357_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/jac\/dkz554","volume":"75","author":"D Armenia","year":"2020","unstructured":"Armenia, D. et al. HIV MDR is still a relevant issue despite its dramatic drop over the years. J. Antimicrob. Chemother. 75, 1301\u20131310 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"3357_CR7","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","volume":"34","author":"KL Bajema","year":"2020","unstructured":"Bajema, K. L. et al. Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. AIDS 34, 2051\u20132059 (2020).","journal-title":"AIDS"},{"key":"3357_CR8","unstructured":"HIV Drug Resistance: Brief Report 2024 (World Health Organization, 2024); iris.who.int\/bitstream\/handle\/10665\/376039\/9789240086319-eng.pdf?sequence=1"},{"key":"3357_CR9","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1371\/journal.pmed.0030356","volume":"3","author":"RS Hogg","year":"2006","unstructured":"Hogg, R. S. et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 3, e356 (2006).","journal-title":"PLoS Med."},{"key":"3357_CR10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"M Kozal","year":"2020","unstructured":"Kozal, M. et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N. Engl. J. Med. 382, 1232\u20131243 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu, B. et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N. Engl. J. Med. 379, 645\u2013654 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer, S. et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793\u20131803 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR13","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","volume":"226","author":"NA Margot","year":"2022","unstructured":"Margot, N. A. et al. Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir. J. Infect. Dis. 226, 1985\u20131991 (2022).","journal-title":"J. Infect. Dis."},{"key":"3357_CR14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1802264","volume":"380","author":"CY Wang","year":"2019","unstructured":"Wang, C. Y. et al. Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption. N. Engl. J. Med. 380, 1535\u20131545 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105151","volume":"104","author":"MA Rai","year":"2024","unstructured":"Rai, M. A. et al. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV. EBioMedicine 104, 105151 (2024).","journal-title":"EBioMedicine"},{"key":"3357_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick, T. S. et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study. JAMA Oncol. 5, 1332\u20131339 (2019).","journal-title":"JAMA Oncol."},{"key":"3357_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","volume":"584","author":"JO Link","year":"2020","unstructured":"Link, J. O. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584, 614\u2013618 (2020).","journal-title":"Nature"},{"key":"3357_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/COH.0000000000000713","volume":"17","author":"H Dvory-Sobol","year":"2022","unstructured":"Dvory-Sobol, H., Shaik, N., Callebaut, C. & Rhee, M. S. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr. Opin. HIV AIDS 17, 15\u201321 (2022).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"3357_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-011110-130254","volume":"6","author":"S Moir","year":"2011","unstructured":"Moir, S., Chun, T. W. & Fauci, A. S. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223\u2013248 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"3357_CR20","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/S0140-6736(03)15022-2","volume":"362","author":"SG Deeks","year":"2003","unstructured":"Deeks, S. G. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362, 2002\u20132011 (2003).","journal-title":"Lancet"},{"key":"3357_CR21","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMp1710608","volume":"377","author":"C Beyrer","year":"2017","unstructured":"Beyrer, C. & Pozniak, A. HIV drug resistance\u2014an emerging threat to epidemic control. N. Engl. J. Med. 377, 1605\u20131607 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR22","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","volume":"10","author":"O Ogbuagu","year":"2023","unstructured":"Ogbuagu, O. et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial. Lancet HIV 10, e497\u2013e505 (2023).","journal-title":"Lancet HIV"},{"key":"3357_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan, R. & Uldrick, T. S. HIV-associated cancers and related diseases. N. Engl. J. Med. 378, 1029\u20131041 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR24","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1182\/blood.V97.7.2130","volume":"97","author":"MQ Du","year":"2001","unstructured":"Du, M. Q. et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97, 2130\u20132136 (2001).","journal-title":"Blood"},{"key":"3357_CR25","doi-asserted-by":"crossref","unstructured":"West, R. E. 3rd, Oberly, P. J., Riddler, S. A., Nolin, T. D. & Devanathan, A. S. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: application to therapeutic monitoring. J. Chromatogr. B 1230, 123905 (2023).","DOI":"10.1016\/j.jchromb.2023.123905"},{"key":"3357_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"3357_CR27","doi-asserted-by":"publisher","first-page":"100243","DOI":"10.1016\/j.xcrm.2021.100243","volume":"2","author":"CN Levy","year":"2021","unstructured":"Levy, C. N. et al. A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. Cell Rep. Med. 2, 100243 (2021).","journal-title":"Cell Rep. Med."},{"key":"3357_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","volume":"16","author":"PP Rose","year":"2000","unstructured":"Rose, P. P. & Korber, B. T. Detecting hypermutations in viral sequences with an emphasis on G \u2013>A hypermutation. Bioinformatics 16, 400\u2013401 (2000).","journal-title":"Bioinformatics"},{"key":"3357_CR29","doi-asserted-by":"publisher","first-page":"vev003","DOI":"10.1093\/ve\/vev003","volume":"1","author":"DP Martin","year":"2015","unstructured":"Martin, D. P., Murrell, B., Golden, M., Khoosal, A. & Muhire, B. RDP4: detection and analysis of recombination patterns in virus genomes. Virus Evol. 1, vev003 (2015).","journal-title":"Virus Evol."},{"key":"3357_CR30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"3357_CR31","doi-asserted-by":"crossref","unstructured":"Larsson, A. AliView: a fast and lightweight alignment viewer and editor for large datasets. Bioinformatics 30, 3276\u20133278 (2014).","DOI":"10.1093\/bioinformatics\/btu531"},{"key":"3357_CR32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","volume":"37","author":"BQ Minh","year":"2020","unstructured":"Minh, B. Q. et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol. Biol. Evol. 37, 1530\u20131534 (2020).","journal-title":"Mol. Biol. Evol."},{"key":"3357_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nmeth.4285","volume":"14","author":"S Kalyaanamoorthy","year":"2017","unstructured":"Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat. Methods 14, 587\u2013589 (2017).","journal-title":"Nat. Methods"},{"key":"3357_CR34","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1002\/cpbi.96","volume":"69","author":"G Yu","year":"2020","unstructured":"Yu, G. Using ggtree to visualize data on tree-like structures. Curr. Protoc. Bioinformatics 69, e96 (2020).","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"3357_CR35","first-page":"138","volume":"9","author":"RR Hudson","year":"1992","unstructured":"Hudson, R. R., Boos, D. D. & Kaplan, N. L. A statistical test for detecting geographic subdivision. Mol. Biol. Evol. 9, 138\u2013151 (1992).","journal-title":"Mol. Biol. Evol."},{"key":"3357_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/bioinformatics\/bti079","volume":"21","author":"SL Pond","year":"2005","unstructured":"Pond, S. L., Frost, S. D. & Muse, S. V. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21, 676\u2013679 (2005).","journal-title":"Bioinformatics"},{"key":"3357_CR37","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3357_CR38","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/s41591-021-01503-6","volume":"27","author":"J Blazkova","year":"2021","unstructured":"Blazkova, J. et al. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nat. Med. 27, 1893\u20131898 (2021).","journal-title":"Nat. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03357-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03357-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03357-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:03:00Z","timestamp":1739901780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03357-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3357"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03357-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.Y., R.R. and K.L. report receiving research support from Celgene (now Bristol-Myers Squibb), CTI BioPharma (a Sobi A.B. Company), PDS Biotech, and Janssen Pharmaceuticals, drugs for clinical trials from Merck, EMD-Serano and Eli Lilly, and preclinical material from Lentigen Technology through CRADAs or MTAs with the NCI. R.Y. is a co-inventor of US Patent 10,001,483 entitled \u2018Methods for the treatment of Kaposi\u2019s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds and uses of biomarkers\u2019. An immediate family member of R.Y. is a co-inventor on patents or patent applications related to internalization of target receptors, epigenetic analysis and ephrin tyrosine kinase inhibitors. All rights, title, and interest to these patents have been assigned to the U.S. Department of Health and Human Services; the government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}